Epirubicin vs doxorubicin in soft tissue sarcomas
1998

High-dose Epirubicin vs Standard-dose Doxorubicin for Soft Tissue Sarcomas

Sample size: 334 publication Evidence: moderate

Author Information

Author(s): OS Nielsen, P Dombemowsky, H Mouridsen, D Crowther, J Verweij, J Buesa, W Steward, S Daugaard, M van Glabbeke, A Kirkpatrick, T Tursz

Primary Institution: Centre for Bone and Soft Tissue Sarcomas, Aarhus University Hospital

Hypothesis

Does high-dose epirubicin provide better outcomes than standard-dose doxorubicin in treating advanced soft tissue sarcomas?

Conclusion

High-dose epirubicin did not improve progression-free survival, overall survival, or response rate compared to standard-dose doxorubicin.

Supporting Evidence

  • Both high-dose epirubicin schedules showed more toxicity than doxorubicin.
  • Median survival was similar across all treatment groups.
  • Response rates were disappointingly low compared to previous studies.

Takeaway

Doctors tested a stronger medicine, epirubicin, to see if it worked better than a regular one, doxorubicin, for treating a type of cancer, but it didn't help more than the regular one.

Methodology

Patients with advanced soft tissue sarcomas were randomly assigned to receive either standard-dose doxorubicin or high-dose epirubicin in two different schedules.

Limitations

The study faced high toxicity in the epirubicin groups and did not show improved response rates.

Participant Demographics

Median age was 52 years, with a performance status of 0-2; 51% were men and 49% women.

Statistical Information

P-Value

0.93

Confidence Interval

95% CI 7-22%

Statistical Significance

p=0.93

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication